Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals was a global specialty biopharmaceutical company with a complex history, culminating in a strategic breakup. Its mission centered on developing and commercializing therapies for severe conditions in autoimmune, rare diseases, and critical care. Key achievements included the commercialization of products like TERLIVAZ® for HRS-1 and the resolution of significant litigation through bankruptcy. The company's final strategy involved merging with Endo and subsequently separating into two focused companies to unlock value and streamline operations.

Core capabilities in complex drug development, formulation, and manufacturing, particularly for sterile injectables, controlled substances, and difficult-to-produce dosage forms, rather than a singular proprietary discovery platform.

Keenova competes with targeted therapies in immunology and critical care, while Par Health operates in the highly competitive, low-margin generics and sterile injectables space against large global players. The separation aims to enhance competitiveness by aligning cost structures and strategies.